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OBJECTIVES We assessed the clinical efficacy of single-site left ventricular (LV) pacing and determined the
impact of baseline conduction delay severity on the magnitude of benefit.
BACKGROUND Multisite biventricular pacing can improve heart failure (HF) symptoms in patients with an
intraventricular conduction delay by resynchronizing abnormal ventricular contractions and
improving LV systolic function.
METHODS Eighty-six patients with at least New York Heart Association functional class II HF, chronic
LV systolic dysfunction, normal sinus rhythm, and a QRS interval over 120 ms were
implanted for atrial-synchronized LV pacing. The single-blinded, randomized, controlled,
crossover study stratified patients 1:1 by the baseline QRS interval into long (QRS150 ms)
and short (QRS 120 to 150 ms) groups, which were compared during a three-month period
of active (univentricular) pacing and a three-month period of inactive (ventricular inhibited)
pacing. The primary end point was peak oxygen consumption (VO2) followed by anaerobic
threshold, distance walked in 6 min, and quality-of-life questionnaire score.
RESULTS Twelve patients were withdrawn before randomization and 17 could not complete both study
periods. The short QRS group did not improve in any end point with active pacing. For the
long QRS group, peak VO2 increased 2.46 ml/min/kg (p  0.001), the anaerobic threshold
increased 1.55 ml/min/kg (p  0.001), the distance walked in 6 min increased 47 m (p 
0.024), and the quality-of-life score improved 8.1 points (p  0.004).
CONCLUSIONS Left ventricular pacing significantly improves exercise tolerance and quality of life in patients
with chronic HF, LV systolic dysfunction, and a QRS interval over 150 ms. (J Am Coll
Cardiol 2003;42:2109–16) © 2003 by the American College of Cardiology Foundation
Despite pharmacologic treatments with angiotensin-
converting enzyme inhibitors (1,2), beta-blockers (3–5), and
spironolactone (6), chronic heart failure (HF) remains a
leading cause of hospitalization and an economic burden
(7,8). Multisite biventricular pacing has recently been
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shown to improve exercise capacity and quality of life,
reduce hospitalization, and slow disease progression in
severe HF patients with an intraventricular conduction
delay associated with abnormal ventricular contraction se-
quences (9–11). Biventricular pacing is believed to resyn-
chronize the abnormal contraction sequences to increase
pumping effectiveness without increasing the heart rate or
myocardial oxygen consumption (12,13).
Using only left ventricular (LV) pacing may simplify
cardiac resynchronization therapy (CRT) (14). Hemody-
namic studies have shown that atrial-synchronized biven-
tricular and LV pacing are nearly equivalent in their ability
to increase LV pump function in HF patients in normal
sinus rhythm (15,16). A small, short-term, randomized,
crossover study found that either kind of pacing similarly
increased exercise capacity and improved quality of life (17).
A prolonged QRS duration is widely regarded as a
prerequisite for using CRT, but a threshold for clinical
effectiveness has not been established, although hemody-
namic improvement is more frequently observed in patients
with a QRS interval 155 ms (18). A prolonged QRS
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duration may also predict a therapy benefit for patients with
indications for an implantable cardioverter-defibrillator
(ICD) (19), but it has not been shown to predict a benefit
for patients in New York Heart Association (NYHA)
functional class II.
The objective of this single-blinded, randomized, con-
trolled, crossover study was to assess the clinical efficacy of
atrial-synchronized LV pacing in patients with stable
NYHA functional class II HF, including patients with
standard indications for an ICD but without standard
pacemaker indications (20), who were stratified by QRS
duration as an index of the severity of intraventricular
conduction delay.
METHODS
Patient selection. Patients 18 to 75 years old who met the
selection criteria were enrolled after giving written, in-
formed consent. Patients had dilated cardiomyopathy of
any etiology with a LV ejection fraction 30% and peak
oxygen consumption (VO2) 18 ml/min/kg on the maxi-
mum exercise test. All patients were in normal sinus
rhythm. Patients were in NYHA functional class II on
optimal individual drug therapy and had not been hospital-
ized for HF in the month before enrollment. One-half of
the patients enrolled had a QRS duration between 120 and
150 ms and the other one-half had QRS 150 ms.
Patients were excluded if they had a history of chronic or
recurrent atrial fibrillation or flutter within the last six
months, aortic or mitral valve stenosis or previous valve
replacement or reconstruction, previous (within three
months) or scheduled coronary revascularization or other
cardiac surgery, unstable angina, myocardial infarction
(within previous three months), acute cardiac failure crisis or
dependency on intravenous inotropes, renal insufficiency
requiring hemodialysis, severe obstructive pulmonary dis-
ease, hypertrophic obstructive cardiomyopathy, amyloidosis,
poorly controlled diabetes mellitus, or a life expectancy 6
months due to other medical conditions.
Study design. The study was performed at nine investiga-
tional centers, following local ethics committee approval.
Enrollment began September 1998 and ended January
2001. The study was designed as a six-month, randomized
crossover comparing three months of atrial-synchronized
univentricular (active) pacing with three months of
ventricular-inhibited (inactive) pacing at a lower rate of 40
beats/min, with the two pacing periods occurring in random
order for each patient (Fig. 1). After a baseline evaluation,
patients were stratified prospectively into two groups ac-
cording to their QRS duration, as assessed by 12-lead
surface electrocardiography and measured by the electrocar-
diographic core center. Patients with QRS 150 ms were
assigned to the long QRS group, and those with QRS
between 120 and 150 ms to the short QRS group. Then
patients underwent an invasive procedure to evaluate their
acute hemodynamic response to pacing and to select the
best site for permanent ventricular pacing. The device was
implanted in a second procedure, and proper device opera-
tion subsequently was verified within five days. Then pa-
tients were randomly assigned to a treatment sequence
(active pacing first or inactive pacing first) following ran-
domization in blocks of size 8, which was separate for each
QRS group. Randomization was followed by the two
crossover periods during which patients were switched
between active and inactive pacing while blinded as to
treatment. After the crossover periods, devices were pro-
grammed to active pacing in all patients, who were followed
until one year after implantation. Only the six-month
crossover study results are reported here.
Hemodynamic evaluation. Patients were evaluated in the
electrophysiology laboratory to select the pacing site and
atrioventricular (AV) delay that provided the best hemody-
namic response. This was determined by the largest increase
in aortic pulse pressure and LV maximum pressure rate
increase measured by a dual-pressure transducer catheter
Abbreviations and Acronyms
AV  atrioventricular
CI  confidence interval
CRT  cardiac resynchronization therapy
HF  heart failure
ICD  implantable cardioverter-defibrillator
LV  left ventricle/ventricular
LVAD  left ventricular assist device
NYHA  New York Heart Association
PATH-CHF  PAcing THerapies for Congestive Heart
Failure
RV  right ventricle/ventricular
VO2  oxygen consumption
Figure 1. Study design. Patients were randomly assigned to three months each of active pacing (atrial-synchronous ventricular) and inactive pacing
(ventricular-inhibited with a minimum pacing rate of 40 beats/min).
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inserted into the LV via the femoral artery. For this test,
standard electrophysiologic catheters were advanced from
the femoral vein to pace inside the right ventricle (RV). An
over-the-wire EASYTRAK lead (model 4512, Guidant
Corp., St. Paul, Minnesota) was advanced from the jugular
vein into the coronary sinus to pace LV sites through the
coronary veins. Left ventricular pacing was compared at two
to four different sites in all patients. Right ventricular pacing
was tested only in patients having right bundle branch
block. The best pacing site was documented radiographi-
cally to guide permanent lead placement during device
implantation. Details of the hemodynamic evaluation pro-
tocols and instrumentation have been previously described
(21,22).
Device implantation. All patients received dual-chamber
pulse generators for atrial-synchronized univentricular pac-
ing. In accordance with current ICD guidelines (20),
patients at high risk of sudden death received an ICD
(model 1831, 1851, 1821, or 1823, Guidant Corp.) and an
endocardial shocking lead implanted in the RV (Endotak
models 0125, 0135, 0145, 0144, 0148, and 0155, Guidant
Corp.). All other patients received a pacemaker (model
1273, 1274, 1270, 1280, or 1241, Guidant Corp.). A
conventional atrial lead was placed high in the right atrium.
One ventricular lead for pacing was placed at the site
selected by the hemodynamic evaluation. For the RV, a
conventional RV pacing lead was implanted. For the LV, an
epicardial lead (Medtronic, models 4968 and 10366 [Min-
neapolis, Minnesota]; Guidant Corp., model 4316) was
implanted via a limited thoracotomy in all patients with an
ICD and initially in some patients with a pacemaker. Later,
pacemaker patients were implanted with a transvenous LV
pacing lead (EASYTRAK model 4512 or ITM 428-07,
Guidant Corp.). Positioning of the LV lead was guided by
a venogram and fluoroscopy during implantation to be as
close as possible to the site selected by the hemodynamic
evaluation and confirmed later by chest X-ray.
At randomization, devices were programmed to a mini-
mum pacing rate of 40 beats/min and a maximum pacing
rate determined by the patient’s heart rate during maximum
exercise at the baseline evaluation. Inactive pacing was
selected by programming a ventricular demand mode caus-
ing inhibition of ventricular pacing. Active pacing was
selected by programming the atrial-synchronous mode with
the AV delay determined by the hemodynamic evaluation.
Clinical assessment. Four clinical measures were assessed
at the baseline evaluation and at the end of each crossover
period. A maximum exercise test on a bicycle was performed
to measure peak VO2 and VO2 at the anaerobic threshold,
using the V-slope method (23). Submaximal exercise was
measured by the distance walked in 6 min, according to the
method of Bittner (24). Quality of life was assessed by the
Minnesota Living With Heart Failure Questionnaire score,
which ranges from 0 (best) to 105 (worst) (25). Patient
functional status was assessed by the NYHA functional
classification.
End points. The primary end point was an improvement in
exercise capacity, as assessed first by peak VO2, second by
VO2 at the anaerobic threshold during maximum exercise
testing, and third by the distance walked in 6 min. The
secondary end points were quality-of-life score and NYHA
functional classification.
Statistical analysis. Enrollment and sample size were es-
timated from the results of the PAcing THerapies for
Congestive Heart Failure (PATH-CHF) study (17,22),
based on an expected improvement of 12.5% in the weakest
primary end point (VO2 at the anaerobic threshold). For a
5% significance level and 80% power, a total sample size of
64 full crossover data sets was required. Due to the expected
mortality and dropout rates, we planned to enroll 100
patients.
An independent statistician performed all data analyses.
End points could be assessed only in patients with no
missing data after completion of both crossover periods.
Baseline characteristics were compared by the unpaired t
test for continuous variables, the Wilcoxon test for walk
distance and quality-of-life score, and the Fisher exact test
for discrete data. The clinical effects of pacing were tested by
calculating for each clinical measure the difference of the
second minus the first crossover period value for each
patient and then comparing all the patient differences
between the two pacing sequences (active first or inactive
first) by the unpaired t test for VO2 measures and by the
Wilcoxon rank-sum test for walk distance, quality-of-life
score, and NYHA functional classification (26,27). Para-
metric estimation of treatment effects and confidence inter-
vals was used for all variables and calculated from the
differences between the active and inactive pacing mean
values for the two pacing sequences. The treatment-period
interaction (residual or carryover effect) was tested by a t test
applied to the individual sums of the first and second period
data. When a pacing effect was significant for all patients,
the effect was tested by the same statistical methods for the
long and short QRS patient groups. A statistical result of p
 0.05 was considered necessary for significance.
RESULTS
Study population. A total of 101 patients were enrolled in
the study. After three patients were withdrawn for valve
replacement and limited life-expectancy, a hemodynamic
evaluation was attempted in 98 patients and successful in 92
patients. The coronary sinus could not be cannulated in two
patients; a lateral or posterior LV coronary vein was inac-
cessible in two patients; and there was dissection of the
coronary venous intima in two patients. Three other pa-
tients were withdrawn after hemodynamic evaluation due to
consent withdrawal, recurrent atrial tachycardia, and infec-
tion. The remaining 89 patients were randomized. The
results of all randomized patients have been reported at a
conference (28). Three of these patients received RV pacing
for right bundle branch block. They have been excluded
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from the present analysis in order to report the results on the
86 randomized patients receiving LV pacing. Table 1 lists
their baseline clinical characteristics. The intraventricular
conduction delay was diagnosed as left bundle branch block
in 76 patients (88%) and right bundle branch block in 1
patient (1%); it was nonspecific in 9 patients (11%). All
patients were symptomatic despite optimal pharmacologic
treatment at baseline, including angiotensin-converting en-
zyme inhibitors or angiotensin II receptor blockers in 99%
of patients and beta-blockers in 73% of patients. Study
investigators were prospectively instructed to not modify the
patients’ medications during the crossover study, except for
diuretics, unless such a change would be required for patient
safety. There were no significant changes in medication
from baseline to the conclusion of the crossover study in any
patient group.
Hemodynamic evaluation. Based on the hemodynamic
evaluation, the best univentricular pacing was LV pacing for
all 85 patients presenting with left bundle branch block or
nonspecific block and for one patient presenting with right
bundle branch block. The best LV pacing site was in a
lateral or posterior vein rather than the anterior vein (29).
When pacing at the selected pacing sites with the best AV
delay (mean 119  32 ms), the aortic pulse pressure
increased an average of 9.9  11%, and the LV maximum
positive pressure rate change increased 19.9  20%.
Implantation. Thirty-four patients were implanted with
an ICD and 52 patients were implanted with a pacemaker.
All 86 patients were implanted with a LV pacing lead; 61
patients received an epicardial lead and 25 received a
transvenous lead. Transvenous lead implantation was suc-
cessful in 93% of patients (25 successes of 27 attempts).
Randomization. The 86 implanted patients were random-
ized to the two treatment sequences with a nearly equal
distribution of long and short QRS group patients in each
sequence (Table 1). There were no significant differences in
Table 1. Baseline Clinical Characteristics of Patients Randomized in the Study
Characteristic
Randomization Group
All
Patients
(n  86)
Active
First
(n  43)
Inactive
First
(n  43)
p
Value*
Long QRS
Active
First
(n  20)
Long QRS
Inactive
First
(n  21)
p
Value†
Short QRS
Active
First
(n  23)
Short QRS
Inactive
First
(n  22)
p
Value‡
Gender (M/F) 57/29 30/13 27/16 0.649 15/5 11/10 0.197 15/8 16/6 0.749
Age (yrs) 60  9 61  9 58  8 0.102 60  11 62  6 0.457 63  8 55  9 0.002
NYHA class (II/III or IV) 28/58 16/27 12/31 0.490 8/12 4/17 0.181 8/15 8/14 1.000
CAD 38% 44% 33% 0.375 45% 24% 0.197 43% 41% 1.000
LBBB 88% 91% 86% 0.738 95% 95% 1.000 87% 77% 0.459
QRS interval (ms) 155  20 154  18 157  23 0.463 169  13 176  16 0.143 140  9 139  7 0.513
PR interval (ms) 195  32 190  36 200  27 0.132 181  39 206  30 0.027 197  32 194  24 0.754
SBP (mm Hg) 113  16 112  17 114  15 0.422 111  14 113  20 0.711 112  19 116  9 0.438
Beta-blocker 73% 72% 74% 1.000 80% 71% 0.719 65% 77% 0.514
Antiarrhythmic 16% 26% 7% 0.038 30% 10% 0.130 22% 5% 0.187
LV ejection fraction (%) 23  7 23  7 23  8 0.619 25  8 20  8 0.100 23  6 25  7 0.233
Peak oxygen uptake
(ml/min/kg)
13.3  2.7 13.2  2.8 13.4  2.5 0.650 12.3  2.6 12.9  2.1 0.425 14.0  2.8 13.9  2.8 0.957
Distance walked in
6 min (m)
407  81 400  69 413  91 0.557 415  54 381  87 0.197 387  79 444  86 0.043
Quality-of-life score 42  18 41  21 43  15 0.622 44  21 45  12 0.990 38  21 41  17 0.679
*Comparison of active first and inactive first groups. †Comparison of long QRS active first and inactive first groups. ‡Comparison of short QRS active first and inactive first
groups. Data are presented as the number of patients, mean value  SD, or percentage of patients.
CAD  coronary artery disease; LBBB  left bundle branch block; LV  left ventricular; NYHA  New York Heart Association; SBP  systolic blood pressure.
Table 2. End Points After Three Months of Inactive or Active Pacing
Study Group n Active Pacing Inactive Pacing p Value
Peak oxygen uptake (ml/min/kg)
Active first sequence 31 15.1  3.2 13.5  3.0 0.001
Inactive first sequence 32 15.3  3.2 14.1  3.2
Oxygen uptake at anaerobic threshold
(ml/min/kg)
Active first sequence 31 10.4  2.2 9.4  2.0 0.001
Inactive first sequence 32 10.3  2.0 9.6  2.0
Distance walked in 6 min (m)
Active first sequence 34 437  83 409  91 0.021
Inactive first sequence 35 468  85 444  74
Quality-of-life score
Active first sequence 31 23  18 28  25 0.015
Inactive first sequence 34 20  18 25  14
Data are presented as the mean value  SD.
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baseline characteristics between patients assigned to differ-
ent sequences (Table 1).
Safety. Seventeen patients did not complete the two cross-
over periods. Three patients were withdrawn immediately
after randomization. One had misplaced leads; another
received an elective left ventricular assist device (LVAD);
and the third was implanted with an ICD device plus a
pacemaker.
Five patients dropped out during an active pacing period.
Two patients without an ICD had a sudden cardiac death.
One patient developed a left-sided pleural effusion related to
the epicardial lead implantation. Two patients were unwill-
ing to comply with the study protocol.
Nine patients dropped out during an inactive pacing
period. Three patients died (two of them without an ICD
by sudden cardiac death). Three patients developed acute
HF decompensation (two of them were prematurely
switched to active pacing), and the third received a LVAD.
One patient developed ventricular tachyarrhythmia and had
a replacement biventricular ICD implanted. One patient
developed untreatable atrial tachyarrhythmia. One patient
developed bronchitis requiring frequent hospitalization.
Figure 2. Peak oxygen consumption at each evaluation point during the study. Mean peak oxygen consumption (with standard error of the mean bars) for
patients in the active first and inactive first pacing sequences (A), for the subset of patients in the long QRS group (QRS 150 ms) (B), and for the subset
of patients in the short QRS group (QRS 120 to 150 ms) (C). CO1  first crossover period; CO2  second crossover period.
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Clinical results. Table 2 shows the results for the 69
patients who completed the crossover period. With active
pacing, peak VO2 increased 1.37 ml/min/kg (95% confi-
dence interval [CI] 1.99 to 0.76; p  0.001) (Fig. 2A), and
VO2 at the anaerobic threshold increased 0.87 ml/min/kg
(95% CI 1.35 to 0.40; p  0.001), compared with inactive
pacing. The distance walked in 6 min was 26 m longer with
active pacing (95% CI 48 to 5; p  0.021). The quality-of-
life score improved 4.7 points with active pacing (95% CI
8.5 to 0.9; p  0.015). The NYHA functional class
significantly improved by 0.25 class points with active
pacing (95% CI 0.38 to 0.11; p  0.001). No carryover or
period effects were observed. There were no significant
differences in any end point improvement between patients
with a pacemaker and patients with an ICD, or between
patients paced with LV coronary vein leads and those with
epicardial screw-in leads.
The clinical effects of active pacing were distinctly differ-
ent between patients in the long QRS group (Table 3) and
those in the short QRS group (Table 4). With active pacing,
the long QRS group exhibited significant improvements
over inactive pacing in peak VO2 (2.46 ml/min/kg) (Fig.
2B), VO2 at the anaerobic threshold (1.55 ml/min/kg),
distance walked in 6 min (47 m), and the quality-of-life
score (8.1 points), whereas the short QRS group did not
have an improvement in peak VO2 (Fig. 2C) nor any other
end point measure. Considering individual results, 71% of
patients in the long QRS group and 38% of patients in the
short QRS group had increased peak VO2 by1 ml/min/kg
with active pacing.
DISCUSSION
This study shows that atrial-synchronized LV pacing sig-
nificantly improves maximal and submaximal exercise ca-
pacity, functional status, and quality of life in patients with
moderate to severe HF, normal sinus rhythm, and intraven-
tricular conduction delay, but without a standard pacemaker
indication. The short-term benefits were only evident
among patients with a QRS duration150 ms. The clinical
improvements with LV pacing of patients with a QRS
duration 150 ms are similar in magnitude to those
reported for biventricular pacing in a trial with a nearly
identical study design (9). These conclusions are unchanged
by including the results from the three randomized patients
who received RV pacing (28). Also, the results were similar
Table 3. End Points After Three Months of Inactive or Active Pacing for Patients in the Long
QRS Group (QRS 150 ms)
Study Group n Active Pacing Inactive Pacing p Value
Peak oxygen uptake (ml/min/kg)
Active first sequence 16 15.6  3.6 13.0  3.5 0.001
Inactive first sequence 15 15.4  2.9 13.1  2.8
Oxygen uptake at anaerobic threshold
(ml/min/kg)
Active first sequence 16 10.5  2.5 8.9  2.0 0.001
Inactive first sequence 15 10.7  1.4 9.2  1.3
Distance walked in 6 min (m)
Active first sequence 17 462  79 407  117 0.024
Inactive first sequence 17 447  72 407  61
Quality-of-life score
Active first sequence 17 24  19 32  27 0.004
Inactive first sequence 17 17  13 25  15
Data are presented as the mean value  SD.
Table 4. End Points After Three Months of Inactive or Active Pacing for Patients in the Short
QRS Group (QRS 120 to 150 ms)
Study Group n Active Pacing Inactive Pacing p Value
Peak oxygen uptake (ml/min/kg)
Active first sequence 15 14.5  2.5 14.1  2.4 0.363
Inactive first sequence 17 15.3  3.4 15.0  3.4
Oxygen uptake at anaerobic threshold
(ml/min/kg)
Active first sequence 15 10.4  2.0 9.9  2.0 0.418
Inactive first sequence 17 10.0  2.5 10.0  2.4
Distance walked in 6 min (m)
Active first sequence 17 413  81 411  60 0.382*
Inactive first sequence 18 488  93 479  68
Quality-of-life score
Active first sequence 14 22  18 23  23 0.766
Inactive first sequence 17 23  21 24  14
*Period interaction effect was significant (p  0.006). Data are presented as the mean value  SD.
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for patients paced with different kinds of LV leads, although
most patients had epicardial leads, which may have been
placed at locations different from those commonly accessible
with a transvenous approach.
Peak VO2 measured during maximal exercise testing is
widely regarded as a reference measure of HF severity (30).
Left ventricular pacing increased peak VO2 by a mean of
2.46 ml/min/kg over inactive pacing for patients with a
QRS duration 150 ms, which is more than twice the
1-ml/min/kg increase considered clinically significant (31–
33). Heart failure patients unable to walk at least 375 m in
6 min are reported to have nearly twice the mortality and
hospitalization rates of patients who can walk farther (34).
For our patients with a QRS duration 150 ms, the
distance walked in 6 min increased by 47 m with LV pacing.
For patients with a QRS duration 150 ms, the quality of
life, as assessed with the Minnesota Questionnaire (25),
improved by a mean 8.1 points with LV pacing, which is
more than the 5-point improvement observed in HF pa-
tients treated with enalapril (35).
It has been suggested that CRT requires simultaneous
stimulation of both ventricles (9). Our results show that LV
pacing is similarly effective, at least over a three-month
period, for patients with normal sinus rhythm and an
intraventricular conduction delay. Differences may emerge
with longer treatment periods or in different patient popu-
lations. This clinical result mirrors hemodynamic tests that
have shown both biventricular and LV pacing to increase
LV systolic function equivalently in the presence of normal
sinus rhythm (15,16). Nearly all patients in these studies
had LV conduction disturbances, often diagnosed as left
bundle branch block (which occurred in 88% of our pa-
tients). For these patients, pre-exciting only the delayed LV
may improve LV contraction synchrony, despite creating a
left-to-right electrical asynchrony (36), or may resynchro-
nize the ventricles by combining with the intrinsic depolar-
ization of the interventricular septum and RV.
By prospectively stratifying patients into short and long
QRS groups, we were able to show that the degree of benefit
from LV pacing depends on the magnitude of the patients’
baseline QRS duration. The QRS threshold of 150 ms used
to separate patients was suggested by previous hemody-
namic studies (16,18). All the statistically significant clinical
improvements we observed can be attributed to patients
with a QRS duration 150 ms; these patients are also most
likely to have improved systolic function (18). However,
38% of individuals with a QRS duration 150 ms had
increased peak VO2 by more than 1 ml/min/kg with LV
pacing. Therefore, other patient characteristics may be
important determinants of pacing effectiveness for patients
with a QRS duration between 120 and 150 ms (37–40).
The Multicenter InSync Randomized Clinical Evaluation
(MIRACLE) study, which compared six months of biven-
tricular CRT with no-CRT in a similar HF population, did
not find a statistically significant influence of the baseline
QRS interval on the magnitude of CRT effect on NYHA
functional class, quality-of-life score, and distance walked in
6 min in a retrospective subanalysis (p  0.10) (11). This
subanalysis does not necessarily conflict with our prospective
results, as the MIRACLE study may have been underpow-
ered to detect the influence of QRS duration, due to, for
example, unbalanced representation of short and long QRS
patients and/or large variability in their end points.
Earlier studies have focused on NYHA functional class as
an indication for patients likely to benefit from resynchro-
nization pacing. Patients in NYHA functional class II have
been excluded from previous trials because they were not
expected to benefit measurably. We have demonstrated a
benefit in a population that included 33% of patients in
NYHA functional class II with peak VO2 below 18 ml/min/
kg. All of these NYHA functional class II patients exhibited
an intraventricular conduction delay, and 43% had a QRS
duration 150 ms, putting them in the category of patients
most likely to benefit from CRT.
There were no differences in end point outcomes for the
40% of patients who were implanted with an ICD. How-
ever, all five deaths during the crossover phase occurred in
patients implanted with a pacemaker lacking defibrillation
capability, including four who had a sudden cardiac death.
Randomized studies with large numbers of patients and
long follow-up periods will be necessary to assess the effect
of resynchronization with or without ICD on mortality and
morbidity (41).
Conclusions. Cardiac resynchronization by LV pacing sig-
nificantly improved the maximal and submaximal exercise
capacity, quality of life, and functional status of HF patients.
These benefits were demonstrated for the whole patient
cohort, but patients who experienced the most benefit had
the longest conduction delays, as indicated by a QRS
duration 150 ms. Longer follow-up will determine
whether this apparent differential benefit is sustained.
Reprint requests and correspondence: Dr. Angelo Auricchio,
Department of Cardiology, University Hospital, Leipzigerstr. 44,
39120 Magdeburg, Germany. E-mail: angelo.auricchio@medizin.
uni-magdeburg.de.
REFERENCES
1. The CONSENSUS Trial Study Group. Effects of enalapril on
mortality in severe congestive heart failure: results of the COoperative
North Scandanavian ENalapril SUrvival Study (CONSENSUS).
N Engl J Med 1987;316:1429–35.
2. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared
with captopril on mortality in patients with symptomatic heart failure:
randomized trial—the Losartan Heart Failure Survival Study ELITE
II. Lancet 2000;355:1582–7.
3. Leizorovicz A, Lechat P, Cucherat M, Bugnard F. Bisoprolol for the
treatment of chronic heart failure: a meta-analysis on individual data of
two placebo-controlled studies—CIBIS and CIBIS II (Cardiac Insuf-
ficiency BIsoprolol Study). Am Heart J 2002;143:301–7.
4. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol
CR/XL Randomised Intervention Trial in Congestive Heart Failure
(MERIT-HF). Lancet 1999;353:2001–7.
5. Eichhorn EJ, Bristow MR. The Carvedilol Prospective Randomized
Cumulative Survival (COPERNICUS) trial. Curr Control Trials
Cardiovasc Med 2001;2:20–3.
2115JACC Vol. 42, No. 12, 2003 Auricchio et al.
December 17, 2003:2109–16 Left Ventricular Pacing in HF Patients
6. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on
morbidity and mortality in patients with severe heart failure. N Engl
J Med 1999;341:709–17.
7. Advisory Council to Improve Outcomes Nationwide in Heart Failure.
Consensus recommendations for the management of chronic heart
failure. Am J Cardiol 1999;83:1A–38A.
8. Berry C, Murdoch DR, McMurray JJ. Economics of chronic heart
failure. Eur J Heart Fail 2001;3:283–91.
9. Cazeau S, Leclercq C, Lavergne T, et al. Effects of multisite biven-
tricular pacing in patients with heart failure and intraventricular
conduction delay. N Engl J Med 2001;344:873–80.
10. Stellbrink C, Breithardt O, Franke A, et al. Impact of cardiac resynchro-
nization therapy using hemodynamically optimized pacing on left ven-
tricular remodeling in patients with congestive heart failure and ventricular
conduction disturbances. J Am Coll Cardiol 2001;38:1957–65.
11. Abraham W, Fisher W, Smith A, et al. Cardiac resynchronization in
chronic heart failure. N Engl J Med 2002;346:1845–53.
12. Nelson GS, Berger RD, Fetics BJ, et al. Left ventricular or biventricu-
lar pacing improves cardiac function at diminished energy cost in
patients with dilated cardiomyopathy and left bundle-branch block.
Circulation 2000;102:3053–9.
13. Leclercq C, Kass DA. Retiming the failing heart: principles and
current clinical status of cardiac resynchronization. J Am Coll Cardiol
2002;39:194–201.
14. Touiza A, Etienne Y, Gilard M, Fatemi M, Mansourati J, Blanc JJ.
Long-term left ventricular pacing: assessment and comparison with
biventricular pacing in patients with severe congestive heart failure.
J Am Coll Cardiol 2001;38:1966–70.
15. Kass DA, Chen CH, Curry C, et al. Improved left ventricular mechanics
from acute VDD pacing in patients with dilated cardiomyopathy and
ventricular conduction delay. Circulation 1999;99:1567–73.
16. Auricchio A, Stellbrink C, Block M, et al. The effect of pacing
chamber and atrio-ventricular delay on acute systolic function of paced
patients with congestive heart failure. Circulation 1999;99:2993–3001.
17. Auricchio A, Stellbrink C, Sack S, et al. Long-term clinical effect of
hemodynamically optimized cardiac resynchronization therapy in pa-
tients with heart failure and ventricular conduction delay. J Am Coll
Cardiol 2002;39:2026–33.
18. Nelson G, Curry C, Wyman B, et al. Predictors of systolic augmen-
tation from left ventricular preexcitation in patients with dilated
cardiomyopathy and intraventricular conduction delay. Circulation
2000;101:2703–9.
19. Kuhlkamp V, and the InSync 7272 ICD World Wide Investigators.
Initial experience with an implantable cardioverter-defibrillator incor-
porating cardiac resynchronization therapy. J Am Coll Cardiol 2002;
39:790–7.
20. Gregoratos G, Cheitling MD, Conill A, et al. ACC/AHA guidelines
for implantation of cardiac pacemakers and antiarrhythmic devices: a
report of the American College of Cardiology/American Heart Asso-
ciation Task Force on Practice Guidelines (Committee on Pacemaker
Implantation). J Am Coll Cardiol 1998;31:1175–209.
21. Stellbrink C, Auricchio A, Butter C, et al. Pacing therapies in
congestive heart failure II study. Am J Cardiol 2000;86 Suppl:138K–
43K.
22. Auricchio A, Stellbrink C, Sack S, et al. The PAcing THerapy for
Congestive Heart Failure (PATH-CHF) study: rationale, design, and
endpoints of a prospective randomized multicenter study. Am J
Cardiol 1999;83 Suppl:130D–5D.
23. Beaver WL, Wasserman K, Whipp BJ. A new method for detecting
anaerobic threshold by gas exchange. J Appl Physiol 1986;60:2020–7.
24. Bittner V. Six-minute walk test in patients with cardiac dysfunction.
Cardiologia 1997;42:897–902.
25. Rector TS, Kubo SH, Cohn JN. Patients’ self-assessment of their
congestive heart failure. II. Content, reliability, and validity of a new
measure—the Minnesota Living With Heart Failure Questionnaire.
Heart Fail 1987;3:198–209.
26. Hill M, Armitage P. The two-period cross-over clinical trial. Br J Clin
Pharmacol 1979;8:7–20.
27. Lehmacher W. Analysis of the crossover design in the presence of
residual effects. Stat Med 1991;10:891–9.
28. North American Society of Pacing and Electrophysiology Conference
2002, Late Breaking Clinical Trials II. Available at: http://www.
naspehighlights.org/summary/summary.asp?sid1&stid12&ld2002-
05-10. Accessed February 10, 2002.
29. Butter C, Auricchio A, Stellbrink C, et al. Effect of resynchronization
therapy stimulation site on the systolic function of heart failure
patients. Circulation 2001;104:3026–9.
30. Weber KT, Kinasewitz GT, Janicki JS, Fishman AP. Oxygen utiliza-
tion and ventilation during exercise in patients with chronic cardiac
failure. Circulation 1982;65:1213–23.
31. Weber KT, Janicki JS, Maskin CS. Response in aerobic capacity in
patients randomly placed on pirbuterol or placebo during a controlled
clinical trial. Circulation 1986;73 Suppl III:III111–6.
32. Mancini DM, Eisen H, Kussmaul W, Mull R, Edmunds H, Wilson
J. Value of peak exercise oxygen consumption for optimal timing of
cardiac transplantation in ambulatory patients with heart failure.
Circulation 1991;83:778–86.
33. Myers J, Gullestad L, Vagelos R, et al. Clinical, hemodynamics and
cardiopulmonary exercise test determinants of survival in patients
referred for evaluation of heart failure. Ann Intern Med 1998;129:
286–293.
34. Bittner V, Weiner DH, Yusuf S, et al., the SOLVD Investigators.
Prediction of mortality and morbidity with a 6-minute walk test in
patients with left ventricular dysfunction. JAMA 1993;270:1702–7.
35. Rector TS, Kubo SH, Cohn JN. Validity of the Minnesota Living
With Heart Failure Questionnaire as a measure of therapeutic re-
sponse to enalapril or placebo. Am J Cardiol 1993;71:1106–7.
36. Leclercq C, Faris O, Tunin R, et al. Systolic improvement and
mechanical resynchronization does not require electrical synchrony in
the dilated failing heart with left bundle-branch block. Circulation
2002;106:1760–3.
37. Auricchio A, Kloss M, Trautmann SI, Rodner S, Klein H. Exercise
performance following cardiac resynchronization therapy in patients
with heart failure and ventricular conduction delay. Am J Cardiol
2002;89:198–203.
38. Ansalone G, Giannantoni P, Ricci R, et al. Doppler myocardial
imaging in patients with heart failure receiving biventricular pacing
treatment. Am Heart J 2001;142:881–96.
39. Sogaard P, Kim WY, Jensen HK, et al. Impact of acute biventricular
pacing on left ventricular performance and volumes in patients with
severe heart failure: a tissue Doppler and three-dimensional echocar-
diographic study. Cardiology 2001;95:173–82.
40. Breithardt O, Stellbrink C, Kramer A, et al. Echocardiographic
quantification of left ventricular asynchrony predicts an acute hemo-
dynamic benefit of cardiac resynchronization therapy. J Am Coll
Cardiol 2002;40:536–45.
41. Bristow MR, Feldman AM, Saxon LA, and for the COMPANION
Steering Committee and Companion Clinical Investigators. Heart
failure management using implantable devices for ventricular resyn-
chronization: comparison of medical therapy, pacing and defibrillation
in chronic heart failure (COMPANION) trial. J Card Fail 2000;6:
276–85.
APPENDIX
Independent Data and Safety Monitoring Committee: Dr. Jorg
Neuzner, Kassel, and Dr. Joachim Winter, Du¨sseldorf,
Germany. Independent Statistician: Prof. Lehmacher, Ko¨ln,
Germany. Other Investigators: Helmut Klein, MD, Christof
Huth, MD, Michael Kloss, MD, and Silke Trautmann,
MD, Otto-von-Guericke-Universita¨t, Magdeburg, Germany;
Ole A. Breithardt, MD, Universita¨tsklinikum RWTH,
Aachen, Germany; Michael Schlegl, MD, Deutsches Herz-
zentrum, Berlin, Germany; Frank R. Heinzel and A. H.
O¨ffner, MD, Universita¨tsklinikum, Essen, Germany; Barbara
Lamp, MD, Herzzentrum Nordrhein-Westfalen, Bad Oeyn-
hausen, Germany; Willem P. Beukema, MD, Isala Klinieken,
Zwolle, The Netherlands; Rainer Gradaus, MD, West-
falische Wilhelms Universita¨t, Mu¨nster, Germany; O¨zlem
Stange, MD, Stiftsklinik Augustinum, Mu¨nchen, Ger-
many; and Patricia F. A. Bakker, MD, Academisch Ziek-
enhuis, Utrecht, The Netherlands.
2116 Auricchio et al. JACC Vol. 42, No. 12, 2003
Left Ventricular Pacing in HF Patients December 17, 2003:2109–16
